增生性瘢痕组织中血管形成的形态学

目的 研究血管形成在增生性瘢痕形成过程中的作用。方法 通过免疫组织化学方法采用CD34抗体对增生性瘢痕组织的微血管进行染色。结果 增生期的增生性瘢痕组织中微血管的含量明显高于萎缩期的增生性瘢痕及正常手术后瘢痕。结论 瘢痕的增生可能具有一定的血管依赖性。     

前列腺癌肿瘤血管生成的研究

目的：探讨肿瘤微血管与前列腺癌生长,转移的关系。方法：应用免疫组化技术结合放射免疫测定检测第Ⅷ因子相关抗原和前列腺特异性抗原（PSA）在19例前列腺癌和40例前列腺增生中的表达和平均值及其相关关系。结果：前列腺癌组织中微血管密度（MVD）和PSA值明显高于前列腺增生,转移性前列腺癌MVD和PSA值高于非转移性前列腺癌,前列腺癌MVD与PSA呈正相关,结论：血管形成与前列腺癌的发生,发展和转移密切相关,肿瘤的增长和转移有赖于肿瘤血管的生成。     

苏拉明对肺癌血管生成的抑制作用

目的　研究苏拉明对肺癌血管生成的抑制作用及其机制。方法　采用细胞培养和免疫组织化学的方法离体研究肺癌A5 49细胞、人血管内皮ECV 30 4细胞VEGF及其受体 (Flt、KDR)的表达及苏拉明的影响。结果　苏拉明对肺癌细胞产生和分泌VEGF无影响 ;ECV 30 4细胞KDR、Flt的蛋白表达在苏拉明浓度为 0 .2 5ng/ml和 2 .5ng/ml时 ,受到显著抑制 ;而苏拉明浓度为 0 .2 5ng/ml和 2 5ng/ml时Flt的表达 ,以及苏拉明浓度为 2 .5ng/ml和 2 5ng/ml时KDR的表达则无明显变化 (与对照组比较 ,P >0 .0 5 ) ;苏拉明对A5 49、ECV 30 4细胞增生无影响。结论　苏拉明抑制肺癌血管生成的作用机制可能是通过抑制血管内皮细胞上的VEGF受体表达 ,减少VEGF与其受体结合所致。     

c-met癌基因与乳腺癌血管生成的相关性研究

目的探讨原癌基因c-met在乳腺癌血管生成中的作用及其临床意义,为寻求抗人乳腺癌血管生成药物提供依据。方法应用SP免疫组化和计算机图像分析技术,对80例乳腺癌、20例乳腺纤维腺瘤的微血管密度和c-met蛋白表达进行定量测定。结果乳腺癌组织微血管计数、c-met阳性表达与组织学分级、淋巴结转移、肿瘤分期显著相关(P<0．01)。高微血管计数与c-net阳性表达显著相关(P<0．01)。结论原癌基因c-met激活参与调控乳腺癌的肿瘤血管生成,是一重要的预后因素。     

血管内皮生长因子在乳腺癌中的表达及其与P53蛋白的关系

目的 :探讨血管内皮生长因子 (vascularendotherialgrowthfactor ,VEGF)在乳腺癌中的表达及其与乳腺癌P5 3蛋白在乳腺癌中的表达之间的关系 ,以及它们与乳腺癌临床病理特征间的关系。方法 :采用免疫组织化学方法检测 88例乳腺癌 ,10例正常乳腺组织以及 10例乳腺良性肿瘤手术标本的VEGF和P5 3蛋白的表达。结果 :在 88例乳腺癌病例中 ,有淋巴结转移的VEGF阳性表达率 (94.2 9% )明显高于无淋巴结转移的VEGF阳性表达率 (49.0 6 % ) (P <0 .0 0 1) ,VEGF阳性表达率与乳腺癌肿瘤大小无关系 (P >0 .1)。P5 3蛋白表达与乳腺癌淋巴结状况 (P >0 .5 )及肿瘤大小 (P >0 .1)无关系。在VEGF表达阳性患者的P5 3蛋白表达阳性率 (45 .76 % )明显高于VEGF表达阴性患者的P5 3蛋白表达阳性率 17.2 4% (P <0 .0 1)。结论 :VEGF在乳腺癌的发生发展及转移中发挥重要作用 ;P5 3基因失活和突变能降低血管生成阻止因子的分泌从而激发VEGF在肿瘤中的表达 ,促使乳腺癌的发生发展和转移。     

卵巢恶性肿瘤VEGF mRNA和bFGF mRNA的表达及其意义

应用原位分子杂交技术研究卵巢恶性肿瘤组织中VEGFmRNA和bFGFmRNA的表达及其意义。结果发现 :浆液性腺癌和内胚窦癌两者表达阳性率高于粘液性腺癌和颗粒细胞瘤 ;临床分期Ⅰ期和未转移病例两者表达阳性率低于临床分期Ⅲ～Ⅳ期和转移病例。结果提示VEGFmRNA和bFGFmRNA表达与卵巢恶性肿瘤病理类型、临床分期和转移发生关系密切 ,阳性表达者可能预后较差。     

血管生长素对缺血心肌促血管生长作用的初步观察

目的：探索血管生长素（ａｎｇｉｏｇｅｎｉｎ,ＡＮＧ）对缺血性心肌的促血管生长作用,以评坐其应用于生物治疗的可行性。方法：以先期成功表达的基因重组人血管生长素衍生物Ａｓｐ１１６Ｈｉｓ。对民肌梗死模型兔的缺血心肌边缘部作直接心肌内注射。注射后５ｄ行冠状动脉血管造影,并取注射点心肌切片作常规病理理苏木精＝工染色,ＶＢ染色,Ⅷ因子相关抗原免疫组化标记。结果：用药心脏表面注射点周围心肌缺血情况较对照组明显闰     

Pathogenetic role and clinical significance of interleukin-1β in cancer

In recent years, pro-oncogenic mechanisms of the tumour microenvironment (ТМЕ) have been actively discussed. One of the main cytokines of the TМЕ is interleukin-1 beta (IL-1β), which exhibits proinflammatory properties. Some studies have shown an association between an increase in IL-1β levels and tumour progression. The purpose of this review is to analyse the pathogenic mechanisms induced by IL-1β in the TМЕ, as well as the diagnostic significance of the presence of IL-1β in patients with cancer and the efficacy of treatment with IL-1β inhibitors. According to the literature, IL-1β can induce an increase in tumour angiogenesis due to its effects on the differentiation of epithelial cells, pro-angiogenic molecule secretion and expression of adhesion molecules, thus increasing tumour growth and metastasis. IL-1β is also involved in the suppression of anti-tumour immune responses. The expression and secretion of IL-1β has been noted in various types of tumours. In some clinical studies, an elevated level of IL-1β was found to be associated with low efficacy of anti-cancer therapy and a poor prognosis. In most experimental and clinical studies, the use of IL-1β inhibitors contributed to a decrease in tumour mass and an increase in the response to anti-tumour drugs.     

骨肉瘤iNOS过度表达与血管生成及预后的关系

目的 探讨骨肉瘤中诱导型一氧化氮合酶（ｉＮＯＳ）的表达及其与血管生成和预后的关系。方法 应用免疫组化方法检测８０例骨肉瘤标本ｉＮＯＳ的表达,ＦⅧ－ＲＡ和ＣＤ３１免疫组化染色显示肿瘤内微血管密度。结果 ８０例骨肉瘤中５２例ｉＮＯＳ阳性（６５％）,肿瘤细胞境质中的巨噬细胞和部分血管内皮细胞均为阳性。ｉＮＯＳ阳性表达和肿瘤内微血管密度（ＭＶＤ）显著正相关,而且ｉＮＯＳ阳性组病人生成率显著低于ｉＮＯＳ阴性     

Involvement of nitric oxide in the inhibition of angiogenesis by interleukin-2

Interleukin-2 (IL-2), an immunoregulatory cytokine possessing antitumour activity, is an inducer of nitric oxide (NO) synthesis in mice and man. In this study, the possibility that IL-2 possesses antiangiogenic properties that account for its antitumour effects in vivo was examined. IL-2 caused a dose-dependent inhibition of angiogenesis in the chick embryo chorioallantoic membrane (CAM). This inhibition was completely reversed by the NO synthase inhibitor N^G-nitro-L-arginine methylester (L-NAME). Furthermore, IL-2 was capable of stimulating NO synthase activity in the CAM in vitro and this effect was suppressed by L-NAME. Addition of IL-2 to human umbilical vein endothelial cells (HUVECs) in culture, had no effect on their growth characteristics. These results suggest that IL-2 may be an important antiangiogenic molecule causing its effect via nitric oxide synthesis. The antiangiogenic activity of IL-2 may be, at least in part, responsible for its antitumour properties.